This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ripertamab
DrugBank Accession Number
DB16314
Background

Ripertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of S-chop(cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of Differentiation Antigen 20)-positive DLBCL Patients).

Type
Biotech
Groups
Investigational
Synonyms
  • Immunoglobulin g1-kappa, anti-(homo sapiens ms4a1 (membrane-spanning 4-domains subfamily a member 1, cd20)), chimeric monoclonal antibody
  • Immunoglobulin igg1, anti-(human cd20 antigen) (human-mus musculus monoclonal disulfide sct400 .gamma.1-chain), disulfide with human-mus musculus monoclonal sct400 .kappa.-chain, dimer
  • Ripertamab
External IDs
  • SCT-400
  • SCT400

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
URS0374MIV
CAS number
2249927-04-4

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2Unknown StatusTreatmentB-Cell Non-Hodgkin Lymphoma (NHL)1
1CompletedTreatmentB-Cell Non-Hodgkin Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 15, 2020 20:02 / Updated at February 21, 2021 18:55